Using group data to treat individuals: Understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence

International Journal of Epidemiology

Volumn 45, Issue 6, 2016, Pages 2184-2193

  Dahabreh, Issa J ^a   Hayward, Rodney ^b   Kent, David M ^c  

^a BROWN UNIVERSITY   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c Institute for Clinical Research and Health Policy Studies   (United States)

Author keywords

Effect measure modification; Heterogeneity of treatment effects; Statistical interaction; Subgroup analysis

Indexed keywords

ANALYTICAL METHOD; DISEASE TREATMENT; EPIDEMIOLOGY; HEALTH CARE; HEALTH RISK; HETEROGENEITY; MEDICINE; PRECISION;

ANALYSIS; ARTICLE; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; EVIDENCE BASED MEDICINE; HETEROGENEITY OF TREATMENT EFFECT ANALYSIS; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; THERAPY EFFECT; CLINICAL PRACTICE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; TRENDS;

DATA INTERPRETATION, STATISTICAL; HUMANS; PATIENT-CENTERED CARE; PRACTICE PATTERNS, PHYSICIANS'; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85017107370     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyw125     Document Type: Article

References (78)

1. Abraham I. More research is needed -but what type? BMJ 2010;342:c4662.
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-95.
3. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987;316:250-58.
4. Robins JM. Confidence intervals for causal parameters. Stat Med 1988;7:773-85.
5. Copas JB. Randomization models for the Matched and Unmatched 2 × 2 Tables. Biometrika 1973;60:467-76.
6. Holland PW. Statistics and causal inference. J Am Stat Assoc 1986;81:945-60.
7. Greenland S. Randomization, statistics, and causal inference. Epidemiology 1990;1:421-29.
8. Rubin D. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol 1974;66:688-701.
9. Rubin DB. Bayesian inference for causal effects:The role of randomization. Ann Stat 1978;6:34-58.
10. Greenland S. Choosing effect measures for epidemiologic data. J Clin Epidemiol 2002;55:423-24.
11. Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol 1987;125:761-68.
12. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004;160:301-05.
13. VanderWeele TY. Confounding and effect modification:distribution and measure. Epidemiol Methods 2012;1:55-82.
14. Maldonado G, Greenland S. Estimating causal effects. Int J Epidemiol 2002;31:422-29.
15. Suzuki E, Mitsuhashi T, Tsuda T, Yamamoto E. A counterfactual approach to bias and effect modification in terms of response types. BMC Med Res Methodol 2013;13:101.
16. Venn J. The Logic of Chance. 2nd edn. London: Macmillan, 1876.
17. Reichenbach H. The Theory of Probability. Berkeley, CA: University of California Press, 1949.
18. Stern RH. Individual risk. J Clin Hypertens (Greenwich) 2012;14:261-64.
19. Kent DM, Shah ND. Risk models and patient-centred evidence: should physicians expect one right answer? JAMA 2012;307:1585-86.
20. White IR, Elbourne D. Assessing subgroup effects with binary data: can the use of different effect measures lead to different conclusions? BMC Med Res Methodol 2005;5:15.
21. Venekamp RP, Rovers MM, Hoes AW, Knol MJ. Subgroup analysis in randomized controlled trials appeared to be dependent on whether relative or absolute effect measures were used. J Clin Epidemiol 2014;67:410-15.
22. Brumback B, Berg A. On effect-measure modification: Relationships among changes in the relative risk, odds ratio, and risk difference. Stat Med 2008;27:3453-65.
23. Scanlan JP. Assumption of constant relative risk reductions across different baseline rates is unsound (responding to Barratt A, Wyer PC, McGinn T, et al.). Tips for learners of evidence-based medicine:
24. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-58.
25. Cui L, Hung HM, Wang SJ, Tsong Y. Issues related to subgroup analysis in clinical trials. J Biopharm Stat 2002;12:347-58.
26. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5:1-56.
27. Cox DR. Interaction. Int Rev Stat 1984;52:1-24.
28. Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. A framework for the analysis of heterogeneity of treatment effect in patient-centred outcomes research. J Clin Epidemiol 2013;66: 818-25.
29. van Klaveren D, Vergouwe Y, Farooq V, Serruys PW, Steyerberg EW. Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions. J Clin Epidemiol 2015;68:1366-74.
30. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
31. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980;112:467-70.
32. Saracci R. Interaction and synergism. Am J Epidemiol 1980;112:465-66.
33. Greenland S. Basic problems in interaction assessment. Environ Health Perspect 1993;101(Suppl 4):59-66.
34. VanderWeele TJ, Robins JM. Four types of effect modification: a classification based on directed acyclic graphs. Epidemiology 2007;18:561-68.
35. VanderWeele TJ. On the distinction between interaction and effect modification. Epidemiology 2009;20:863-71.
36. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischaemic stroke. Stroke 2006;37:2957-62.
37. Brookes ST, Whitely E, Egger M, Davey Smith G, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004;57:229-36.
38. Schmidt AF, Groenwold RH, Knol MJ et al. Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. J Clin Epidemiol 2014;67:821-29.
39. Sun X, Briel M, Busse JW et al. Credibility of claims of subgroup effects in randomised controlled trials:systematic review. BMJ 2012;344:e1553.
40. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine -reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
41. PCORI (Patient-Centred Outcomes Research Institute) Methodology Committee. The PCORI Methodology Report.
42. http://www.pcori.org/assets/2013/11/PCORI-Methodology-Report.pdf (22March 2016, date last accessed).
43. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
44. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
45. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 2005;365:256-65.
46. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. MilbankQ2004;82:661-87.
47. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 2006;296:1286-89.
48. Davidoff F. Heterogeneity is not always noise:lessons from improvement. JAMA 2009;302:2580-86.
49. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616-19.
50. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005;365:176-86.
51. Greenfield S, Kravitz R, Duan N, Kaplan SH. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 2007;120:S3-9.
52. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010;11:85.
53. Cai T, Tian L, Wong PH, Wei LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 2011;12:270-82.
54. Lu T, Zhao X. Statistical methods for personalized medicine. Advanced Medical Statistics. 2nd edn. Singapore: World Scientific Publishing, 2015.
55. Davey Smith G, Egger M. Who benefits from medical interventions? BMJ 1994;308:72-74.
56. D'Agostino RB Sr, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis 2014;58:1386-93.
57. Selker HP, Griffith JL, Beshansky JR et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med 1997;127:538-56.
58. Thune JJ, Hoefsten DE, Lindholm MG et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 2005;112:2017-21.
59. Kovalchik SA, Tammemagi M, Berg CD et al. Targeting of lowdose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54.
60. Robins JM. Discussion of a paper by Professor Miettinen. Epidemiol Methods 2015;4:33-36.
61. Vickers AJ, Kent DM. The Lake Wobegon effect:Why most patients are at below-average risk. Ann Intern Med 2015;162: 886-67.
62. Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int J Epidemiol 2016;45:2075-88.
63. Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol 1998;148:1117-26.
64. Ioannidis JP, Lau J. The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol 1997;50:1089-98.
65. Kent DM, Schmid CH, Lau J, Selker HP. Is primary angioplasty for some as good as primary angioplasty for all? J Gen Intern Med 2002;17:887-94.
66. Kent DM, Hayward RA, Griffith JL et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 2002;113:104-11.
67. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007;298:1209-12.
68. Dorresteijn JA, Visseren FL, Ridker PM et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 2011;343:d5888.
69. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke 2003;34:464-67.
70. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet 1999;353:2105-10.
71. Hayward RA, Kent DM, Vijan S, Hofer TP. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood) 2005;24:1571-81.
72. Follmann DA, Proschan MA. A multivariate test of interaction for use in clinical trials. Biometrics 1999;55:1151-55.
73. Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes 2014;7: 163-69.
74. Kovalchik SA, De MS, Landi MT et al. A regression model for risk difference estimation in population-based case-control studies clarifies gender differences in lung cancer risk of smokers and never smokers. BMC Med Res Methodol 2013;13:143.
75. Clagget B, Zhao L, Tian L, Castagno D, Wei LJ. Estimating subject-specific treatment differences for risk-benefit assessment with competing risk event-time data. Harvard University, Biostatistics Working Paper Series 2011.
76. Claggett B, Tian L, Castagno D, Wei LJ. Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. Harvard University, Biostatistics Working Paper Series 2012.
77. Pocock SJ, Lubsen J. More on subgroup analyses in clinical trials. N Engl J Med 2008;358:2076-77.
78. Davey Smith G, Egger M. Incommunicable knowledge? Interpreting and applying the results of clinical trials and metaanalyses. J Clin Epidemiol 1998;51:289-95.